Peptide Based Infection Therapeutics may be one method for the development of COVID-19-specific medications because peptides have various benefits. Most COVID-19 patients experienced very minor symptoms, such as a fever, nonproductive cough, and sore throat, which can be adequately managed. However, patients who experience deadly side effects such organ failure, acute heart and renal injury, pulmonary edoema, pneumonia, and acute respiratory distress syndrome (ARDS) have a difficult time being treated, and depending on how serious their condition is, they may pass away. Patients who already have comorbid conditions such cerebral and cardiovascular disorders, diabetes, obesity, cancer, respiratory diseases, and old age and who also have a weakened immune system are most at risk. It has been determined that the virus is zoonotic.
Peptide Based Infection Therapeutics
